Subscribe By RSS or Email
Theralase Could Light Up Cancer Therapeutics

Theralase Could Light Up Cancer Therapeutics

Cancer patients don’t have many good treatment options. Once the disease is detected, most oncologists will surgically remove as much as possible and then use powerful radiation and chemotherapy to kill as many cells in those areas as possible. The side effects from these treatments can be terrible and patients are at a higher risk […]

Exosomes Shine a Light on Alzheimer’s Disease and CTE

Exosomes Shine a Light on Alzheimer’s Disease and CTE

Concussions are common in recreational and professional sports with an estimated 1.6 million sustained concussion-related injuries per year in the U.S. alone. Since concussions aren’t detectable using X-rays or CT scans, they often go undiagnosed and attempts to prevent them have been difficult. These concussions can lead to far more serious problems like chronic traumatic […]

Discovery Could Lead to Major Breakthrough in Alzheimer’s Disease and Other Brain Disorders

Discovery Could Lead to Major Breakthrough in Alzheimer’s Disease and Other Brain Disorders

Some leading scientists are making strides like never before in research for debilitating and deadly diseases, such as Alzheimer’s Disease (AD), Chronic Traumatic Encephalopathy (CTE) and Traumatic Brain Injury (TBI).  Currently, people afflicted with these conditions have little hope to avert disease progression and, sadly, death.  There is reason for optimism, though, with hundreds of […]

Recent Articles:

Value Metrics in Low-Priced Stocks: Oculus Innovative Sciences, Paragon Offshore and CHC Group

Wall Street is chock full of metrics for valuing any given company, including price-to-earnings ratio, price-to-sales ratio, price/earnings to growth (PEG) ratio and so on. With the markets pressing yet again on record highs and

Oculus Innovative Sciences Banking Millions on Ruthigen-Pulmatrix Merger

Funding can be a tricky creature for companies as investors despise hearing the word dilution, but want to see a portfolio company develop products and expand, creating a huge catch-22 situation, especially for small capitalized

Miraculins Takes Next Steps Towards Securing FDA Approval for Scout DS®

Miraculins Inc. (TSX-V: MOM) (OTC: MCUIF), a medical diagnostics company focused on acquiring, developing, and commercializing diagnostic tests and risk assessment technologies for unmet clinical needs, recently announced the provision of pre-submission documentation to the

Time to Take Another Look at Oculus Innovative Sciences

Five years ago, several analysts were covering Oculus Innovative Sciences (NASDAQ: OCLS) with favorable ratings (i.e. “buy,” “market outperform,” etc.), but things have changed as the stock price slid from the area of $20 per

Miraculins Moves Closer to Commercialization

Diabetes is the seventh leading cause of death in the United States with over a million new cases each year, according to the American Diabetes Association, costing the healthcare system $176 billion in direct costs

Miraculins Interviewed by BTV & The Life Sciences Report

Miraculins Inc. (TSX-V: MOM) (OTC: MCUIF), a medical diagnostic company focused on acquiring, developing and commercializing non-invasive technologies for unmet clinical needs, was recently featured on BTV and The Life Sciences Report. President and CEO

321gold Highlights Miraculins’ Potential in Diabetes

Miraculins Inc. (TSX-V: MOM) (OTC: MCUIF), a pre-revenue biotechnology company that acquires, develops and commercializes new, non-invasive diagnostic and risk assessment tests to aid physicians in the earlier diagnosis of disease, was recently featured in

Miraculins: Pioneering a New Approach to Diabetes Screening

Diabetes affects nearly 30 million U.S. citizens – or roughly 10% of the population – with about 27% of those cases going undiagnosed, according to the American Diabetes Association. As well, there are approximately 80

Miraculins Outlines Plans to Further Advance Scout DS® in 2015

Miraculins Inc. (TSX-V: MOM), a medical diagnostics company focused on diagnostic testing and risk assessment technologies addressing unmet clinical needs, recently outlined its plans to pursue Chinese FDA approval, establish full production capabilities, and develop

Miraculins Makes Significant Strides in 2014

Miraculins Inc. (TSX-V: MOM), a medical diagnostic company focused on acquiring, developing, and commercializing diagnostic tests and risk assessment technologies for unmet clinical needs, recently announced a year-end review of its accomplishments in the context

Theralase Anti-Cancer Technology Picks Up Steam

There are many different approaches to treating cancer, ranging from Roche Holding Ltd.’s (OTC: RHHBY) monoclonal antibody Perjeta to Merck & Co. Inc.’s (NYSE: MRK) immunotherapy Keytruda. While both of these drugs have made great

OxySure Systems Signs Exclusive Agreements with Olympian Cliff Meidl

OxySure Systems Inc. (OTC: OXYS), developer of life-saving, easy-to-use emergency oxygen solutions leveraging its “oxygen from powder” technology, recently announced an exclusive long-term agreement with two-time U.S. Olympian Cliff Meidl to become a spokesperson for